Towards more specific treatment for diabetic dyslipidemia

Abstract

Purpose of review Treatment of diabetic dyslipidemia is necessary because of its impact on cardiovascular disease, which is the leading cause of death in patients with diabetes. In the past, standard treatment of diabetic dyslipidemia focused only on correcting lipids. Although this remains the mainstay of treatment, because new antihyperglycemic treatments reduce cardiovascular events with minimal effect on dyslipidemia, a new approach is both timely and relevant. Recent findings LDL-lowering remains the focus of treatment for diabetic dyslipidemia, especially in patients with both diabetes and cardiovascular disease (CVD). Higher intensity statin therapy or lower LDL cholesterol goals are recommended in these patients. Combination therapy, especially with ezetimibe, fibrates, bile acid sequestrants, PCSK9 inhibitors and omega 3 fatty acids should be considered along with selected new agents to reduce glycemia. Summary As diabetic dyslipidemia plays a key role in CVD, aggressive treatment is indicated. New research targets include apo-CIII and lipoprotein(a) [Lp(a)]. In addition, new antihyperglycemic therapy is changing diabetes care and altering treatment guidelines. The most recent American Diabetes Association Standards of Care has expanded its recommendations for people with CVD and diabetes, suggesting that medications validated to improve cardiac health should be strongly considered.

Dietary Supplementation of Vine Tea Ameliorates Glucose and Lipid Metabolic Disorder via Akt Signaling Pathway in Diabetic Rats

“…Most cases of T2D are accompanied by dyslipidemia, which is an important cause of T2D incidence and development and is also a treatable relevant aspect for subsequent cardiovascular complications that may develop in patients with T2D [33,34,35]. The liver is an important metabolic organ in the human body and directly affects the metabolism of glucose and lipids.…”

Dyslipidemia Management in Adults With Diabetes

“…CETP-mediated TG enrichment and increased lipolysis of LDL by hepatic lipase increase the number of atherogenic small dense LDL particles (9,10). The total burden of atherogenic particles and remnants are contributors to elevated non-HDL cholesterol level and Apo B measured in type 2 diabetes (11).…”

Low-Density Lipoprotein Cholesterol Levels Among Individuals Receiving Statin Therapy: Real-World Evidence from India

“…The ACCORD-lipid trial suggested that addition of fenofibrate therapy may reduce CVD events in diabetic patients with hypertriglyceridemia and low HDL-C [28][29][30]. Evidence from multiple studies have evaluated the potential effect of PCSK9 inhibitors, bile acid sequestrants, niacin, omega-3-fatty acids as add-on therapies to statins for patients with diabetes [29,30]. However, the incremental benefit of these drugs in patients with diabetes and comorbid ASCVD needs to be explored further.…”